Vistagen to Present at the Stifel 2024 Healthcare Conference
14 Novembre 2024 - 2:30PM
Business Wire
Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated
to pioneering neuroscience based on nose-to-brain neurocircuitry,
today announced that company management will present and host
one-on-one meetings during the Stifel 2024 Healthcare Conference
taking place November 18 and 19, 2024 in New York City.
Stifel 2024 Healthcare Conference
- Shawn Singh, Chief Executive Officer, will participate in a
fireside chat on Monday, November 18 at 3:35 p.m. Eastern
Time.
A webcast will be accessible through the “Events” page in the
“Investors” section of the Company’s website at www.Vistagen.com.
Investors interested in arranging a one-on-one meeting during the
conference should contact their Stifel representative.
About Vistagen
Headquartered in South San Francisco, CA, Vistagen (Nasdaq:
VTGN) is a late clinical-stage company leveraging its pioneering
neuroscience and deep understanding of nose-to-brain neurocircuitry
to develop and commercialize a broad and diverse pipeline of
intranasal product candidates called pherines. Each pherine product
candidate in Vistagen’s neuroscience pipeline is designed to
rapidly activate olfactory system and brain neurocircuitry to
achieve desired therapeutic benefits and differentiated safety
without requiring systemic absorption or binding to neurons in the
brain. Vistagen’s neuroscience pipeline also includes an oral
prodrug, AV-101, with potential to impact certain neurological
conditions involving the NMDA receptor. Vistagen is passionate
about developing transformative treatment options to improve the
lives of individuals underserved by the current standard of care
for multiple highly prevalent disorders, including social anxiety
disorder, major depressive disorder, and vasomotor symptoms (hot
flashes) associated with menopause. Connect at
www.Vistagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241114792150/en/
Investors: Mark A. McPartland Vistagen Therapeutics
markmcp@vistagen.com
Media: Caren Scannell Vistagen Therapeutics
cscannell@vistagen.com
Vistagen Therapeutics (NASDAQ:VTGN)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Vistagen Therapeutics (NASDAQ:VTGN)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
